JUBILANT PHARMOVA Financial Statement Analysis
|
||
|
The Revenues of JUBILANT PHARMOVA have increased by 7.93% YoY .
The Earnings Per Share (EPS) of JUBILANT PHARMOVA has decreased by -52.53 % YoY. |
||
JUBILANT PHARMOVA Last 5 Annual Financial Results
[BOM: 530019|NSE : JUBLPHARMA]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹7,235 Cr | ₹6,703 Cr | ₹6,282 Cr | ₹6,130 Cr | ₹6,099 Cr |
| Expenses | ₹6,061 Cr | ₹5,802 Cr | ₹5,506 Cr | ₹4,974 Cr | ₹4,702 Cr |
| Operating Profit (Excl OI) | ₹1,174 Cr | ₹901 Cr | ₹776 Cr | ₹1,156 Cr | ₹1,396 Cr |
| Other Income | ₹57 Cr | ₹69 Cr | ₹38 Cr | ₹11 Cr | ₹18 Cr |
| Interest | ₹240 Cr | ₹272 Cr | ₹188 Cr | ₹145 Cr | ₹184 Cr |
| Depreciation | ₹369 Cr | ₹382 Cr | ₹554 Cr | ₹382 Cr | ₹349 Cr |
| Profit Before Tax | ₹981 Cr | ₹171 Cr | ₹28 Cr | ₹630 Cr | ₹871 Cr |
| Profit After Tax | ₹836 Cr | ₹73 Cr | ₹-65 Cr | ₹413 Cr | ₹574 Cr |
| Consolidated Net Profit | ₹839 Cr | ₹77 Cr | ₹-61 Cr | ₹414 Cr | ₹836 Cr |
| Earnings Per Share (Rs) | ₹25.22 | ₹53.13 | ₹4.88 | ₹-3.84 | ₹26.01 |
| PAT Margin (%) | 4.55 | 10.94 | 1.08 | -1.03 | 6.74 |
| ROE(%) | 5.97 | 14.35 | 1.34 | -1.21 | 8.21 |
| ROCE(%) | 8.69 | 13.92 | 5.02 | 2.53 | 9.97 |
| Total Debt/Equity(x) | 0.46 | 0.39 | 0.63 | 0.63 | 0.55 |
Key Financials |
||
| Market Cap | : | ₹ 14,842.8 Cr |
| Revenue (TTM) | : | ₹ 8,279.6 Cr |
| Net Profit(TTM) | : | ₹ 397.8 Cr |
| EPS (TTM) | : | ₹ 25.0 |
| P/E (TTM) | : | 37.3 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| JUBILANT PHARMOVA | 0.1% | -3.8% | -22.5% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.1% | 0.5% | 14% |
| DIVIS LABORATORIES | -0.9% | 21.1% | 25.6% |
| TORRENT PHARMACEUTICALS | -1.3% | 1.1% | 32.7% |
| CIPLA | 0.2% | 2.1% | -5.1% |
| DR REDDYS LABORATORIES | 0.2% | -7.7% | -7.5% |
| MANKIND PHARMA | -1.4% | -3.7% | -5.3% |
| LUPIN | -0.7% | -5.7% | 24% |
| ZYDUS LIFESCIENCES | -0.1% | -3.9% | 14.1% |
JUBILANT PHARMOVA Revenues
[BOM: 530019|NSE : JUBLPHARMA]
| Y-o-Y | 7.93 % |
| 5 Yr CAGR | 4.36 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹7,235 Cr | 7.93 | |
| Mar2025 | ₹6,703 Cr | 6.71 | |
| Mar2024 | ₹6,282 Cr | 2.47 | |
| Mar2023 | ₹6,130 Cr | 0.52 | |
| Mar2022 | ₹6,099 Cr | - | |
JUBILANT PHARMOVA Operating Profit
[BOM: 530019|NSE : JUBLPHARMA]
| Y-o-Y | 30.30 % |
| 5 Yr CAGR | -4.25 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,174 Cr | 30.30 | |
| Mar2025 | ₹901 Cr | 16.05 | |
| Mar2024 | ₹776 Cr | -32.87 | |
| Mar2023 | ₹1,156 Cr | -17.20 | |
| Mar2022 | ₹1,396 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 20.68 % |
| 5 Yr CAGR | -8.26 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 16.22% | 20.68 | |
| Mar2025 | 13.44% | 8.74 | |
| Mar2024 | 12.36% | -34.46 | |
| Mar2023 | 18.86% | -17.64 | |
| Mar2022 | 22.9% | - | |
JUBILANT PHARMOVA Profit After Tax
[BOM: 530019|NSE : JUBLPHARMA]
| Y-o-Y | 988.72 % |
| 5 Yr CAGR | 0.11 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹839 Cr | 988.72 | |
| Mar2025 | ₹77 Cr | Positive | |
| Mar2024 | ₹-61 Cr | Negative | |
| Mar2023 | ₹414 Cr | -50.48 | |
| Mar2022 | ₹836 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -58.41 % |
| 5 Yr CAGR | -9.36 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 4.55 % | -58.41 | |
| Mar2025 | 10.94 % | 912.96 | |
| Mar2024 | 1.08 % | Positive | |
| Mar2023 | -1.03 % | Negative | |
| Mar2022 | 6.74 % | - | |
JUBILANT PHARMOVA Earnings Per Share (EPS)
[BOM: 530019|NSE : JUBLPHARMA]
| Y-o-Y | -52.53 % |
| 5 Yr CAGR | -0.77 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹25 | -52.53 | |
| Mar2025 | ₹53 | 988.73 | |
| Mar2024 | ₹4.88 | Positive | |
| Mar2023 | ₹-3.84 | Negative | |
| Mar2022 | ₹26 | - | |
JUBILANT PHARMOVA Return on Capital Employed (ROCE)
[BOM: 530019|NSE : JUBLPHARMA]
| Y-o-Y | -37.57 % |
| 5 Yr CAGR | -3.38 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 8.69% | -37.57 | |
| Mar2025 | 13.92% | 177.29 | |
| Mar2024 | 5.02% | 98.42 | |
| Mar2023 | 2.53% | -74.62 | |
| Mar2022 | 9.97% | - | |
JUBILANT PHARMOVA Share Price vs Sensex
| Current Share Price | : | ₹931.8 |
| Current MarketCap | : | ₹ 14,842.8 Cr |
| Updated EOD on | : | Aug 07,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| JUBILANT PHARMOVA | 0.1% |
-3.8% |
-22.5% |
| SENSEX | 0.5% |
2.6% |
-3.7% |
JUBILANT PHARMOVA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 250 SMALLCAP INDEX | 2.6% | 4.2% | 4.3% |
| BSE 400 MIDSMALLCAP INDEX | 1.7% | 4.2% | 6.6% |
| BSE 1000 | 1.3% | 3.7% | 3% |
| BSE 500 | 1.1% | 3.6% | 2.6% |
| BSE HEALTHCARE | 0.9% | 4.1% | 11.7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP 500 | 2.8% | 4.7% | NA |
| NIFTY SMALLCAP 250 | 2.4% | 4.3% | 6.1% |
| NIFTY500 SHARIAH | 1.9% | 5.5% | 1.2% |
| NIFTY MIDSMALLCAP400 50:50 | 1.7% | 4% | NA |
| NIFTY 500 EQUAL WEIGHT | 1.7% | 4.2% | 5.7% |
You may also like the below Video Courses
FAQ about JUBILANT PHARMOVA Financials
How the annual revenues of JUBILANT PHARMOVA have changed ?
The Revenues of JUBILANT PHARMOVA have increased by 7.93% YoY .
How the Earnings per Share (EPS) of JUBILANT PHARMOVA have changed?
The Earnings Per Share (EPS) of JUBILANT PHARMOVA has decreased by -52.53 % YoY .
Check out Intrinsic Value of Peers of JUBILANT PHARMOVA
Compare Stock Analytics of Peers of JUBILANT PHARMOVA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
